FTSE MIB
27.113,95 +92,91 (+0,34%) Dow Jones
33.274,15 +415,12 (+1,26%) Nasdaq
12.221,91 +208,43 (+1,74%) Nikkei 225
28.041,48 +258,55 (+0,93%) Petrolio
75,70 +1,33 (+1,79%) Bitcoin EUR
25.998,53 -131,52 (-0,50%)
Sorrento Therapeutics, Inc. (0L85.L)
| Chiusura precedente | 0,3600 |
| Aperto | 0,3652 |
| Denaro | 0,0000 x N/D |
| Lettera | 0,0000 x N/D |
| Min-Max giorno | 0,3652 - 0,3652 |
| Intervallo di 52 settimane | 0,3652 - 0,3652 |
| Volume | |
| Media Volume | N/D |
| Capitalizzazione | 426.699 |
| Beta (5 anni mensile) | 2,18 |
| Rapporto PE (ttm) | N/D |
| EPS (ttm) | -1,5270 |
| Prossima data utili | N/D |
| Rendimento e dividendo (forward) | N/D (N/D) |
| Data ex dividendo | N/D |
| Stima target 1A | N/D |
- GlobeNewswire
Scilex Holding Company Reports Substantial Underreporting of More Than 44 Million Shares of its Common Stock by Brokerage Firms for the Upcoming Annual Meeting of Stockholders Scheduled for April 6, 2023 and Issues a Supplement to its Previously Issued “FAQ” Regarding the Dividend of Scilex Holding Company Common Stock
PALO ALTO, Calif., March 27, 2023 (GLOBE NEWSWIRE) -- Scilex Holding Company (Nasdaq: SCLX, “Scilex”), a subsidiary of Sorrento Therapeutics, Inc. (OTC Market: SRNEQ) (“Sorrento”), announced today that there are more than 44 million shares of its common stock that have not yet been reported by brokers, banks and other nominees (collectively, “brokerage firms”) to Broadridge Financial Solutions, Inc. (“Broadridge”), an independent third party that collects and tabulates stockholder votes for the
- GlobeNewswire
Scilex Holding Company Announces Financing of up to $25 Million to Enhance Commercialization of Three FDA Approved Non-Opioid Pain Management Products
Proceeds from the financing commitment will be used to enhance the launch and commercialization of Scilex’s three FDA-approved non-opioid pain management products (ZTlido®, Gloperba® and Elyxyb™) for the treatment of acute and chronic pain.The financing will enable further investment in Scilex’s non-opioid pain management portfolio, accelerating its mission to launch innovative non-opioid pain management products in major markets. PALO ALTO, Calif., March 21, 2023 (GLOBE NEWSWIRE) -- Scilex Hold
- GlobeNewswire
Scilex Holding Company and CH Trading Group Announce Territory Distribution Agreement to Expand Commercialization of ZTlido® for the Middle East and North Africa (MENA) With $105 Million Minimum Multi-Year Purchase Commitment
CH Trading Group will serve as exclusive territories distributor in the Middle East and North Africa countries with US $105 million minimum purchase commitment.CH Trading Group to immediately start the process to expand commercialization of ZTlido® in Middle East and North Africa markets and has the opportunity to distribute across the broader Islamic world and further expand the relationship for other products in Scilex’s non-opioid pain portfolio. PALO ALTO, Calif., March 08, 2023 (GLOBE NEWSW
